Avicenna Avicenna participates in AI For Health Summit
On 10 November, fiive Avicenna Representatives; Emmanuelle Voisin (Founder and CEO, Neighborhood, Voisin Consulting Life Sciences), Prof. Liesbet Geris (University of Liege) ,Thierry Marchal (Avicenna Alliance Secretary-General), Markus Reiterer (Medtronic Distinguished Scientist) and Simon Sonntag (Virtonomy Co-founder & CEO) will discuss AI and the digitalisation of healthcare at the AI for Health Summit.
More particularly, they will discuss how today we can improve research, development and market access of health care products and what role in silico medicine can play.
Today, in Healthtech, we are held back by the comfort of a "familiar uncertainty" for which we have done little to challenge in the past. Many players in in silico medicine have questioned this status quo. Some have demonstrated that through computational modelling and simulation support, an initial set of evidence generated by a few hundred patients instead of 1000 could be sufficient for approval by regulators, potentially saving millions in drug and medical device development costs and reducing the time to market by years. To make this happen, the alignment of data generators, product developers and regulators is essential.